|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
HUE048876T2
(hu)
|
2011-05-09 |
2020-08-28 |
Mayo Found Medical Education & Res |
Rákos megbetegedések kezelése
|
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
DK3049441T3
(da)
|
2013-09-27 |
2020-02-03 |
Hoffmann La Roche |
Anti-PDL1-antistofformuleringer
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
EP3154586B1
(en)
|
2014-06-13 |
2020-05-27 |
Mayo Foundation for Medical Education and Research |
Treating lymphomas
|
|
US10213513B2
(en)
|
2014-06-16 |
2019-02-26 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
CN107073132B
(zh)
|
2014-10-06 |
2021-08-27 |
梅约医学教育与研究基金会 |
载体-抗体组合物及其制备和使用方法
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
CN107921126A
(zh)
*
|
2015-05-22 |
2018-04-17 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
CN109608544B
(zh)
|
2015-11-17 |
2022-09-16 |
苏州盛迪亚生物医药有限公司 |
Pd-l1抗体、其抗原结合片段及其医药用途
|
|
DK3386541T3
(da)
|
2015-12-07 |
2020-09-28 |
Merck Patent Gmbh |
Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
CN109153719B
(zh)
*
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
WO2017165440A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
EP3432928A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
CN109414500B
(zh)
*
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
|
SMT202100317T1
(it)
|
2016-06-27 |
2021-07-12 |
Morphosys Ag |
Formulazioni di anticorpi anti-cd19
|
|
WO2018027524A1
(en)
*
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN109843336A
(zh)
|
2016-09-01 |
2019-06-04 |
梅约医学教育与研究基金会 |
用于靶向t细胞癌症的方法和组合物
|
|
CN109890419A
(zh)
|
2016-09-01 |
2019-06-14 |
梅约医学教育与研究基金会 |
用于治疗癌症的载体-pd-l1结合剂组合物
|
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
CN109843924A
(zh)
*
|
2016-09-06 |
2019-06-04 |
梅约医学教育与研究基金会 |
治疗表达pd-l1的癌症的方法
|
|
AU2017324947A1
(en)
|
2016-09-06 |
2019-03-28 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
TW201834639A
(zh)
*
|
2017-03-06 |
2018-10-01 |
德商馬克專利公司 |
水性抗體調配物
|
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
SG11201907948TA
(en)
*
|
2017-03-29 |
2019-09-27 |
Celgene Corp |
Formulations comprising pd-1 binding proteins and methods of making thereof
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JOP20190260A1
(ar)
*
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
RU2766590C2
(ru)
|
2017-05-16 |
2022-03-15 |
Цзянсу Хэнжуй Медисин Ко., Лтд. |
Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
CN107384870A
(zh)
*
|
2017-07-31 |
2017-11-24 |
时力生物科技（北京）有限公司 |
一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
EP3664829A4
(en)
*
|
2017-08-09 |
2021-05-05 |
Orionis Biosciences, Inc. |
LIAISON OFFICERS AT PD-1 AND PD-L1
|
|
JP7382922B2
(ja)
*
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
|
|
EP3705134A4
(en)
*
|
2017-11-02 |
2021-07-28 |
Nanjing Shunxin Pharmaceutical Co., Ltd. |
PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
|
|
WO2019134946A1
(en)
|
2018-01-04 |
2019-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
MX2020007406A
(es)
|
2018-01-10 |
2020-09-14 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
|
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
IL277095B2
(en)
*
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
JP2021525806A
(ja)
*
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
TW202035447A
(zh)
*
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
AU2019328632A1
(en)
|
2018-08-27 |
2021-03-25 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
CN113454111A
(zh)
*
|
2018-11-06 |
2021-09-28 |
健玛保 |
抗体配制剂
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
JP2022513693A
(ja)
*
|
2018-11-29 |
2022-02-09 |
ハーバー・バイオメド・セラピューティクス・リミテッド |
抗ｐｄ－ｌ１抗体製剤
|
|
EP3892299A4
(en)
*
|
2018-12-07 |
2022-11-30 |
ONO Pharmaceutical Co., Ltd. |
IMMUNOSUPPRESSANT
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CA3117710A1
(en)
|
2018-12-11 |
2020-06-18 |
Theravance Biopharma R&D Ip, Llc |
Alk5 inhibitors
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
CN113795511B
(zh)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
抗pd-l1双抗体及其用途
|
|
EP3918332B1
(en)
|
2019-01-30 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
PE20212185A1
(es)
|
2019-02-18 |
2021-11-11 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos
|
|
CN109929037B
(zh)
|
2019-04-01 |
2023-03-17 |
华博生物医药技术（上海）有限公司 |
针对程序性死亡配体的结合物及其应用
|
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN114206381A
(zh)
*
|
2019-07-10 |
2022-03-18 |
瑞泽恩制药公司 |
宿主细胞蛋白水平降低的合成物及其制备方法
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
EP4045686A1
(en)
|
2019-10-17 |
2022-08-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
JP7450710B2
(ja)
|
2019-10-21 |
2024-03-15 |
上▲海▼宏成▲薬▼▲業▼有限公司 |
抗ｐｄ－ｌ１抗体及びその製薬用途
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
KR20220104208A
(ko)
|
2019-11-22 |
2022-07-26 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
|
|
JP2023504748A
(ja)
*
|
2019-12-09 |
2023-02-06 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１抗体製剤
|
|
US20230346901A1
(en)
|
2019-12-19 |
2023-11-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
EP4100126A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
WO2021170777A1
(en)
|
2020-02-28 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
|
CN116323607A
(zh)
|
2020-06-10 |
2023-06-23 |
施万生物制药研发Ip有限责任公司 |
用作alk5抑制剂的萘啶衍生物
|
|
EP4189395A1
(en)
|
2020-07-28 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for preventing and treating a cancer
|
|
US11865082B2
(en)
|
2020-09-09 |
2024-01-09 |
Hoffmann-La Roche Inc. |
Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
US20240294645A1
(en)
*
|
2021-06-18 |
2024-09-05 |
Hangzhou Sumgen Biotech Co., Ltd. |
Bispecific fusion protein
|
|
KR20240058149A
(ko)
*
|
2021-09-16 |
2024-05-03 |
허밍버드 바이오사이언스 피티이. 엘티디. |
Vista 항원-결합 분자를 사용한 암의 치료 및 예방
|
|
WO2023075790A1
(en)
*
|
2021-10-29 |
2023-05-04 |
Nascent Biotech, Inc. |
Kits and containers for treating vimentin expressing tumors
|
|
EP4427044A1
(en)
|
2021-11-03 |
2024-09-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
TW202323269A
(zh)
*
|
2021-12-08 |
2023-06-16 |
荷蘭商菲林公司 |
方法
|
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
US20260083725A1
(en)
|
2022-08-10 |
2026-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Sigmari ligand for the treatment of pancreatic cancer
|
|
US20260061031A1
(en)
|
2022-09-14 |
2026-03-05 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
WO2024126750A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Methods for treating cancer
|
|
WO2024192108A1
(en)
|
2023-03-14 |
2024-09-19 |
Evolveimmune Therapeutics, Inc. |
Genetically modified car t cells and methods of making and using the same
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
EP4788839A1
(en)
|
2023-10-03 |
2026-08-12 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
WO2026013071A1
(en)
|
2024-07-09 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Setdb1 inhibitor for use in the treatment of uveal melanoma
|
|
EP4763209A1
(en)
|
2024-12-17 |
2026-06-24 |
Institut National de la Santé et de la Recherche Médicale |
Use of (alpha)s-setmar agonist for preventing or treating glioblastoma
|